

Bernhard Ludvik, M.D.

Associate Professor of Medicine
Medical University of Vienna

CURRICULUM VITAE

Office address:

Department of Internal Medicine III
Division of Endocrinology and Metabolism
Medical University of Vienna
Waehringer Guertel 18-20
1090 Vienna

Tel./Fax: ++43 (0)1 40400-4364

E-mail: bernhard.ludvik@meduniwien.ac.at
Homepage: <http://www.bernhard-ludvik.at/>



PERSONAL DATA

Date and place of Birth:

June 21, 1961 in Vienna

Graduation:

M.D., Feb. 7, 1985, Medical School University of Vienna

PROFESSIONAL CAREER

1985 – 1992

Internship and residency from March 1, 1985 to June 30, 1992 at the Medical Department II, University of Vienna

since July 1, 1991

Specialist in Internal Medicine

1992 - 1994

Research Fellow at the University of California San Diego

since June 27, 1995

Assistant Professor of Medicine

since 1996

Specialist in Endocrinology and Metabolism

since October 1, 1998

Associate Professor of Medicine

since 2004

Diploma in Geriatric Medicine – Austrian Medical Association

since 2004

Diploma in Palliative Care – Austrian Medical Association

CURRENT EMPLOYMENT

Associate Professor of Medicine, Medical University of Vienna; Attending in Internal Medicine and Endocrinology at the Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna (Vienna General Hospital)

Ambulance supervisor of the ambulance of metabolism and diabetes at the Div. of Endocrinology and Metabolism, Dept. of Internal Medicine III

Deputy Head of the Division of Endocrinology and Metabolism, Dept. of Internal Medicine III

Leader of the working group on Obesity and Endocrinology

MEMBERSHIPS

Austrian Medical Association

Austrian Society of Internal Medicine

Austrian Diabetes Association

Austrian Obesity Association

Austrian Society of Endocrinology

American Diabetes Association

European Association for the Study of Obesity (EASO)

European Association for the Study of Diabetes (EASD)

European Group on Insulin Resistance (EGIR)

Federation of International Donau Symposia on Diabetes mellitus

HONORS AND AWARDS

1992	Research Grant „Erste Österreichische Sparkasse“; presented by the Austrian Medical Association
1992-1994	Fellowship Max Kade Foundation; Research at the University of San Diego, California
1995	Hoechst Award presented by the Dean of the Faculty of Medicine of Vienna in
1995	2nd Secretary of the Austrian Society of Internal Medicine
1996-1997	1st Secretary of the Austrian Diabetes Association
1996-1999	1st Secretary of the Federation of the International DONAU-SYMPOSIA on Diabetes mellitus
1996-1998	Vice President of the Austrian Obesity Association
1998-2000	President of the Austrian Obesity Association
1998-2003	Assistant Editor of <i>DIABETOLOGIA</i>
2001	Chairman of the Austrian Obesity Association
2002	2 nd Secretary of the Austrian Society of Internal Medicine
2002-2003	Vice President of the Austrian Obesity Association

2004	Founding Fellow of the SCOPE program (EASO) 2004
2005	2 nd Secretary of the Austrian Society of Internal Medicine
2006-2008	Vice President of the Austrian Diabetes Association

CURRENT POSITIONS

President-of the Austrian Diabetes Association

Chairman of committees: training materials, nutrition, public

Member of the Board of the Austrian Obesity Association

Advisory Board „*Jatros. Zeitschrift für Diabetologie und Stoffwechsel*“

Member of the Editorial Board „*Journal für Ernährungsmedizin*“

Section Editor (clinical aspects and treatment) Obesity facts – The European Journal of Obesity

RESEARCH AREAS

Basic research on pathogenesis and therapy of type 2 diabetes, the metabolic syndrome and obesity

Migration, and application of telemedicine technologies in Diabetology

Clinical research on the treatment of obesity, diabetes and lipid metabolic disorders as a principal investigator of numerous studies and clinical trials in phases 1, 2 and 3

Nutritional Medicine

Original works in many top journals, review articles, book contributions, numerous presentations at national and international congresses, organization of national and international conferences, speaker at training sessions, reviews in top journals (Diabetes Care, Diabetologia, European J. Clin. Investigation)

BIBLIOGRAPHY

ORIGINAL PAPERS AND REVIEWS

1. Hartter E, Weissel M, Stummvoll HK, Woloszczuk W, Punzengruber C, **Ludvik B**: Atrial natriuretic peptide concentrations in blood from right atrium in patient with severe right heart failure. *Lancet* 2:93-94, 1985
2. Weissel M, Punzengruber C, Hartter E, **Ludvik B**, Woloszczuk W: Thyroid hormones and pericardial effusion may influence plasma levels of atrial natriuretic peptide (ANP) in humans. *Klin. Wochenschr.* 64 Suppl 6:93-96, 1986
3. Woloszczuk W, **Ludvik B**: Nachweis und radioimmunologische Quantifizierung von humanem atrialen natriuretischen Peptid im Harn. *Berichte der ÖGKC* 9:65-67, 1986
4. Punzengruber C, Hartter E, Weissel M, Burghuber OC, **Ludvik B**, Woloszczuk W: [Peripheral and right atrial plasma levels of atrial natriuretic peptide and their relation to mean atrial pressure]. *Z.Kardiol.* 76:72-75, 1987

5. **Ludvik B**, Niederle B, Roka R, Scherthaner G, Neuhold N: [Malignant aldosteronoma in the differential diagnosis of Conn syndrome]. *Acta Med.Austriaca* 15:117-120, 1988
6. Hay U, **Ludvik B**, Gisinger C, Scherthaner G: [Lack of effect of ACE inhibition on severe proteinuria in diabetic nephropathy--a 6-month-long study]. *Schweiz.Med.Wochenschr.* 118:165-169, 1988
7. Wrba F, Chott A, **Ludvik B**, Schratte M, Spona J, Reiner A, Scherthaner G, Krisch K: Solid and cystic tumour of the pancreas; a hormonal-dependent neoplasm? *Histopathology* 12:338-340, 1988
8. Wrba F, Chott A, Schratte M, **Ludvik B**, Krisch K, Holzner JH: [Fine-needle puncture cytology of a solid cystic tumor of the pancreas]. *Pathologie* 9:340-344, 1988
9. **Ludvik B**, Scheithauer W, Wrba F, Schratte M, Schiessel R, Scherthaner G: [Gestagen receptor-positive, solid-cystic acinar-cell tumor of the pancreas]. *Dtsch.Med.Wochenschr.* 114:903-906, 1989
10. Hartter E, Svoboda T, Lell B, Schuller M, **Ludvik B**, Woloszczuk W, Prager R: Reduced islet-amyloid polypeptide in insulin-dependent diabetes mellitus. *Lancet* 335:854, 1990
11. Graf H, Watzinger U, **Ludvik B**, Wagner A, Hocker P, Zweymuller KK: Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. *BMJ* 300:1627-1628, 1990
12. **Ludvik B**, Kueenburg E, Brunnbauer M, Scherthaner G, Prager R: The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension. *J.Cardiovasc.Pharmacol.* 18 Suppl 2:S157-S159, 1991
13. Prager R, **Ludvik B**, Hartter E: [Role of amylin in the pathogenesis of type II diabetes mellitus]. *Acta Med.Austriaca* 18:61-62, 1991
14. **Ludvik B**, Peer G, Berzlanovich A, Stifter S, Graf H: Effects of dichloroacetate and bicarbonate on haemodynamic parameters in healthy volunteers. *Clin.Sci.(Colch.)* 80:47-51, 1991
15. Hartter E, Svoboda T, **Ludvik B**, Schuller M, Lell B, Kueenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co- secretion with insulin in humans. *Diabetologia* 34:52-54, 1991
16. **Ludvik B**, Lell B, Hartter E, Schnack C, Prager R: Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. *Diabetes* 40:1615-1619, 1991
17. **Ludvik B**, Kautzky-Willer A, Prager R: Epidemiologie: Ätiologie und neue therapeutische Konzepte bei Adipositas. *Therapiewoche Österreich* 7:14-19, 1992
18. Kautzky-Willer A, Pacini G, **Ludvik B**, Scherthaner G, Prager R: Beta-cell hypersecretion and not reduced hepatic insulin extraction is the main cause of hyperinsulinemia in obese nondiabetic subjects. *Metabolism* 41:1304-1312, 1992
19. **Ludvik B**, Niederle B, Roka R, Neuhold N, Templ M, Scherthaner G: Isolated primary hyperaldosteronism in adrenocortical carcinoma. *Acta Chirurgica Austriaca* 25:212-216, 1993
20. **Ludvik B**, Stifter S, Hartter E, Capek M, Prager R, Graf H: Accresciuti livelli del polipeptide amiloide delle isole non hanno effetto sulla secrezione di insulina in pazienti con danno renale cronico. *Giornale italiano di Diabetologia* 12:204-205, 1993
21. **Ludvik B**, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. *Diabetologia* 36:84-87, 1993

22. Kautzky-Willer A, Pacini G, Weissel M, Capek M, **Ludvik B**, Prager R: Elevated hepatic insulin extraction in essential hypertension. *Hypertension* 21:646-653, 1993
23. **Ludvik B**, Mayer G, Stifter S, Putz D, Barnas U, Graf H: Effects of dichloroacetate on exercise performance in healthy volunteers. *Pflugers Arch.* 423:251-254, 1993
24. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, **Ludvik B**, Strelci C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. *Diabetologia* 37:188-194, 1994
25. **Ludvik B**, Clodi M, Kautzky-Willer A, Schuller M, Graf H, Hartter E, Pacini G, Prager R: Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion. *J.Clin.Invest* 94:2045-2050, 1994
26. Nolan JJ, **Ludvik B**, Beersden P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. *N.Engl.J.Med.* 331:1188-1193, 1994
27. Capek M, Schnack C, **Ludvik B**, Kautzky-Willer A, Banyai M, Prager R: Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study. *Clin.Investig.* 72:961-966, 1994
28. Kautzky-Willer A, Pacini G, Barnas U, **Ludvik B**, Strelci C, Graf H, Prager R: Intravenous calcitriol normalizes insulin sensitivity in uremic patients. *Kidney Int.* 47:200-206, 1995
29. **Ludvik B**, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM: A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. *J.Clin.Invest* 95:2232-2238, 1995
30. **Ludvik B**, Nolan JJ, Baloga J, Sacks D, Olefsky J: Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. *Diabetes* 44:1121-1125, 1995
31. Kotzmann H, Linkesch M, **Ludvik B**, Clodi M, Luger A, Schernthaner G, Prager R, Klauser R: Effect of danazol-induced chronic hyperglucagonaemia on glucose tolerance and turnover. *Eur.J.Clin.Invest* 25:942-947, 1995
32. Thomaseth K, Kautzky-Willer A, **Ludvik B**, Prager R, Pacini G: Integrated mathematical model to assess beta-cell activity during the oral glucose test. *Am.J.Physiol* 270:E522-E531, 1996
33. Kautzky-Willer A, Thomaseth K, Clodi M, **Ludvik B**, Waldhausl W, Prager R, Pacini G: Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. *Metabolism* 45:486-491, 1996
34. Kautzky-Willer A, Thomaseth K, **Ludvik B**, Nowotny P, Rabensteiner D, Waldhausl W, Pacini G, Prager R: Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. *Diabetes* 46:607-614, 1997
35. Nolan JJ, **Ludvik B**, Baloga J, Reichart D, Olefsky JM: Mechanisms of the kinetic defect in insulin action in obesity and NIDDM. *Diabetes* 46:994-1000, 1997
36. **Ludvik B**, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G: Amylin: history and overview. *Diabet.Med.* 14 Suppl 2:S9-13, 1997
37. Thomaseth K, Pacini G, Clodi M, Kautzky-Willer A, Nolan JJ, Prager R, Olefsky JM, **Ludvik B**: Amylin release during oral glucose tolerance test. *Diabet.Med.* 14 Suppl 2:S29-S34, 1997
38. **Ludvik B**: [Amylin/IAPP (islet amyloid polypeptide)--physiology and clinical significance]. *Wien.Klin.Wochenschr.* 109:379-383, 1997

39. Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, Ulm M, Strelci C, **Ludvik B**: Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. *Diabetes Care* 20:1717-1723, 1997
40. **Ludvik B**, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM: Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus. *J.Clin.Invest* 100:2354-2361, 1997
41. **Ludvik B**: [Weight loss by increasing energy consumption and thermogenesis]. *Acta Med.Austriaca* 25:136-137, 1998
42. Clodi M, Thomaseth K, Pacini G, Hermann K, Kautzky-Willer A, Waldhusl W, Prager R, **Ludvik B**: Distribution and kinetics of amylin in humans. *Am.J.Physiol* 274:E903-E908, 1998
43. **Ludvik B**: [Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers]. *MMW.Fortschr.Med.* 142:27-28, 2000
44. Riedl M, **Ludvik B**, Pacini G, Clodi M, Kotzmann H, Wagner O, Kautzky-Willer A, Prager R, Luger A: The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. *Eur.J.Clin.Invest* 30:771-778, 2000
45. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, **Ludvik B**, Prager R, Waldhausl W: Increased plasma leptin in gestational diabetes. *Diabetologia* 44:164-172, 2001
46. Mari A, Pacini G, Murphy E, **Ludvik B**, Nolan JJ: A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. *Diabetes Care* 24:539-548, 2001
47. Tura A, **Ludvik B**, Nolan JJ, Pacini G, Thomaseth K: Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. *Am.J.Physiol Endocrinol.Metab* 281:E966-E974, 2001
48. **Ludvik B**, Mahdjoobian K, Waldhaeusl W, Hofer A, Prager R, Kautzky-Willer A, Pacini G: The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study. *Diabetes Care* 25:239-40, 2002
49. Georg P, Kautzky-Willer A, Mahdjoobian K, Hofer A, Prager R, Pacini G, **Ludvik B**: Influence of metabolic control on splanchnic glucose uptake, insulin sensitivity, and the time required for glucose absorption in patients with type 1 diabetes. *Diabetes Care* 25:2042-2047, 2002
50. **Ludvik B**, Thomaseth K, Nolan, JJ, Clodi M, Prager R, Pacini G: Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. *Eur J Clin Invest* 33, 316-322, 2003
51. Tura A, Pacini G, Kautzky-Willer A, **Ludvik B**, Prager R, Thomaseth K: Basal and dynamic proinsulin-insulin relationship to assess {beta}-cell function during OGTT in metabolic disorders. *Am J Physiol Endocrinol Metab* 285, E155-E162, 2003
52. **Ludvik B**, Waldhaeusl W, Prager R, Kautzky-Willer A, Pacini G: Mode of Action of Ipomoea batatas (Caiapo) in type 2 diabetic patients. *Metabolism* 52:875-880, 2003
53. Pichler B, **Ludvik B**: Future perspectives of pharmacotherapy of obesity. *Journal für Kardiologie* 10:427-429, 2003
54. **Ludvik B**, Neuffer B, Pacini G: Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic patients. *Diabetes Care* 27:436-440, 2004
55. Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R, Buranyi B, Maier C, Luger A, **Ludvik B**: The Impact of Laparoscopic Adjustable Gastric Banding (LABG) on Plasma Ghrelin, Eating Behaviour and Body Weight. *Eur J Clin Invest* 34(8):549-54, 2004

56. Schindler K, **Ludvik B**: Methodische und praktische Aspekte der Bestimmung der Körperzusammensetzung [Assessment of Body Composition - methods and practical aspects]. *Wien Med Wochenschr* 154(13-14):305-12, 2004
57. Tripp B, **Ludvik B**: Medikamentöse Therapie der Adipositas [Pharmacotherapy of Obesity]. *Wien Med Wochenschr* 154(13-14):320-8, 2004
58. Bohdjalian A, Langer FB, Hoda A, Felberbauer FX, Silberhumer G, Zacherl J, Schindler K, Luger A, **Ludvik B**, Prager G: Chirurgische Therapie der Adipositas. *Wien Med Wochenschr* 154(13-14):329-33, 2004
59. Tripp B, **Ludvik B**: Neue Antiadiposita [Novel Anti-Obesity Drugs]. *Acta Medica Austriaca* 31(4):133-138, 2004
60. Cauza E, Hanusch-Enserer U, Strasser B, **Ludvik B**, Metz-Schimmerl S, Pacini G, Wagner O, Georg P, Prager R, Kostner K, Dunky A, Haber P: The Relative Benefits of Endurance and Strength Training on the Metabolic Factors and Muscle Function of People with Type 2 Diabetes Mellitus. *Arch Phys Med Rehabil* 86(8):1527-33, 2005
61. Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, Schindler K, Luger A, **Ludvik B**, Prager G: Sleeve Gastrectomy and Gastric Banding: Effects on Plasma Ghrelin Levels. *Obes Surg* 15(7):1024-9, 2005
62. Cauza E, Hanusch-Enserer U, Strasser B, **Ludvik B**, Kostner K, Dunky A, Haber P: Continuous Glucose Monitoring in Diabetic Long Distance Runners. *Int J Sports Med* 26(9):774-80, 2005
63. Abrahamian H, **Ludvik B**, Schernthaner G, Prager R, Zellenka U, Knudsen L, Wascher T: Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). *Horm Metab Res* 37(11):684-9, 2005
64. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, **Ludvik B**: Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. *J Clin Endocrinol Metab* 91(4):1578-81, 2006
65. Langer FB, Bohdjalian A, Felberbauer FX, Fleischmann E, Reza Hoda MA, **Ludvik B**, Zacherl J, Jakesz R, Prager G: Does gastric dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity? *Obes Surg* 16 (2):166-71, 2006
66. Bohdjalian A, Prager G, Aviv R, Policker S, Schindler K, Kretschmer S, Riener R, Zacherl J, **Ludvik B**: One year experience with Tantalus™: a New Surgical Approach to Treat Morbid Obesity. *Obes Surg* 16(5):627-34, 2006
67. Kautzky-Willer A, Tura A, Winzer C, Wagner OF, **Ludvik B**, Hanusch-Enserer U, Prager R, Pacini G: Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. *Diabetes Obes Metab* 8(5):561-7, 2006
68. Schindler K, Haider D, Wolzt M, Rieger A, Gmeinhardt B, Luger A, Nowotny P, **Ludvik B**: Impact of Antiretroviral Therapy on Visfatin and Retinol Binding Protein 4 in HIV+ Subjects, *Eur J Clin Invest* 36(9):640-6, 2006
69. Riener R, Schindler K, **Ludvik B**: Psychosocial Variables, Eating Behavior, Depression and Binge Eating in Morbidly Obese Subjects. *Eating Behaviors* 7(4):309-14, 2006
70. Dorner T, Fodor JG, Lawrence K, **Ludvik B**, Rieder A: HDL-knowledge in the lay public: results of a representative population survey. *Atherosclerosis* 195(1):195-8, 2007

71. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, **Ludvik B**: Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. *J Clin Endocrinol Metab* 92(3):1168-71, 2007
72. Haider DG, Schindler K, Mittermayer F, Müller M, Nowotny P, Rieger A, **Ludvik B**, Wolzt M: Effect of rosiglitazone on visfatin and retinol binding protein-4 plasma concentrations in HIV-positive patients. *Clin Pharmacol Ther* 81(4):580-5, 2007
73. Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, **Ludvik B**: Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. *Diabetes Obes Metab* 9(5):761-3, 2007
74. Tripp B, **Ludvik B**: Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study. *Wien Med Wochenschr* 157(9-10):223-7, 2007 [German]
75. Anderwald C, Anderwald-Stadler M, Promintzer M, Prager G, Mandl M, Nowotny P, Bischof MG, Wolzt M, **Ludvik B**, Kästenbauer T, Pacini G, Luger A, Krebs M: The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. *Diabetes Care* 30(9):2374-80, 2007
76. Vila G, Maier C, Riedl M, Nowotny P, **Ludvik B**, Luger A, Clodi M: Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. *J Clin Endocrinol Metab* 92(10):3930-4, 2007
77. Kollmann A, Riedl M, Kastner P, Schreier G, **Ludvik B**: Feasibility of a mobile phone-based data service for functional insulin treatment of type 1 diabetes mellitus patients. *J Med Internet Res* 9(5):e36, 2007
78. **Ludvik B**, Hanefeld M, Pacini G: Improved Metabolic Control by Ipomoea (Caiapo) is Associated with Increased Adiponectin and Decreased High Sensitive C-reactive Protein and Fibrinogen Levels in type 2 diabetic subjects. *Diabetes Obes Metab* 10(7):586-92, 2008
79. Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, **Ludvik B**, Silberhumer GR, Prager G, Stulnig TM: Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. *Endocrinology* 149(3):1350-7, 2008
80. Riedl M, Vila G, Maier C, Handisurya A, Shakeri-Manesch S, Prager G, Wagner O, Kautzky-Willer A, **Ludvik B**, Clodi M, Luger A: Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. *J Clin Endocrinol Metab* 93(6):2307-12, 2008
81. Morak J, Schindler K, Goerzer E, Kastner P, Toplak H, **Ludvik B**, Schreier G: A pilot study of mobile phone-based therapy for obese patients. *J Telemed Telecare* 14(3):147-9, 2008
82. Langer FB, Bohdjalian A, Shakeri-Manesch S, Felberbauer FX, Ludvik B, Zacherl J, Prager G: Inadequate Weight Loss vs Secondary Weight Regain: Laparoscopic Conversion from Gastric Banding to Roux-en-Y Gastric Bypass. *Obes Surg* 18(11):1381-6, 2008
83. Brema I, Hatunic M, Finucane F, Burns N, Nolan JJ, Haider D, Wolzt M, Ludvik B: Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus. *Diabetes Obes Metab* 10(7):600-2, 2008
84. Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, Zlabinger GJ, Stulnig TM: CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. *J Clin Endocrinol Metab* 93(8):3215-21, 2008

85. Maier C, Riedl M, Vila G, Nowotny P, Wolzt M, Clodi M, Ludvik B, Luger A: Cholinergic regulation of ghrelin and PYY release may be impaired in obesity. *Diabetes* 57(9):2332-40, 2008
86. Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, Karnieli E, Assalia A, Prager R, Prager: Improvement in glycemic control by gastric electrical stimulation (TANTALUS(TM)) in overweight subjects with type 2 diabetes. *G.Surg Endosc*, 2008, [Epub ahead of print]
87. Vila G, Riedl M, Maier C, Struck J, Morgenthaler NG, Handisurya A, Prager G, Ludvik B, Clodi M, Luger A: Plasma MR-proADM Correlates to BMI and Decreases in Relation to Leptin After Gastric Bypass Surgery. *Obesity (Silver Spring)*, 2009, [Epub ahead of print]
88. Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B: The Effect of Rosiglitazone on Insulin Sensitivity, Beta Cell Function, Bone Mineral Density, and Body Composition in HIV-positive Patients on Highly-active Antiretroviral Therapy (HAART). *Horm Metab Res*, 2009, [Epub ahead of print]

CHAPTERS IN BOOKS

1. Weissel M, Punzengruber C, Hartter E, Burghuber OC, **Ludvik B**, Woloszczuk W: Effect of treatment with L-thyroxine on plasma ANP levels in athyreotic patients: indirect evidence for the necessity of adequate thyroid hormone levels to maintain normal ANP levels. In *Advances in atrial peptide research*. Vol 2 ed. Brenner BM, Saragh JH, Eds. 1988, p. 293-297
2. Graf H, Watzinger U, **Ludvik B**, Wagner A, Höcker B, Zweymüller KK: Eigenblutspende unter Erythropoietin - ein neues Konzept für elektive orthopädische Eingriffe. In *10 Jahre Zweymüller Hüftendoprothese*. Zweymüller KK, Ed. 1990, p. 77-81
3. Kautzky-Willer A, Capek M, Pacini G, **Ludvik B**, Prager R: Insulin secretion, insulin sensitivity and hepatic insulin extraction in essential hypertension. In *Current Topics in Diabetes Research*. Karger Verlag, 1993, p. 250-253
4. **Ludvik B**: Adipositas – Diagnostik und Therapie. In *Ernährungsmedizin*. Widhalm K, Diallo-Ginstl E, Eds. ÖAK 2000, 334-346
5. **Ludvik B**: Konservative Therapie der morbiden Adipositas. In *Morbide Adipositas – Klinik und Therapie*. Hell E, Miller K, Eds. Ecomed 2000, 20-25
6. **Ludvik B**: Sekundäre Diabetesformen. In *Diabetes in der Praxis*. Waldhaeusl W, Gries FA, Scherbaum W, Eds. Springer Verlag Berlin 2004
7. **Ludvik B**: Diabetes mellitus: ein progredientes Krankheitsbild. Therapie, Prävention und Einfluss von Lifestyle. In *Angewandte Anti-Aging-Medizin*. Gasser R (Hg). Verlagshaus der Ärzte 2004

BOOKS

1. **Ludvik B** (Ed.): *Risikofaktor Diabetes – Konzepte für ein Langzeitproblem*. Uni-Med-Verlag Bremen, 1.Aufl. 2004 [ISBN: 3-89599-824-9]
2. **Ludvik B**, Toplak H: *Medikamentöse Therapie der Adipositas*. Springer Verlag Wien, 1.Aufl. 2006 [ISBN: 3-211-83815-5]
3. Mihaljevic K, Feffer S, **Ludvik B**: *Essen mit Spass + Aktivsein mit Mass. So entkommen Sie dem Metabolischen Syndrom*, Verlagshaus der Ärzte, 1. Aufl. 2006 [ISBN: 3-901488-75-8]

4. Pfeiffer A, **Ludvik B**, Kinzl JF: Für immer dünn. [Audio CD - Hörbuch], Galila Hörbuchverlag, 1.Aufl. 2006 [ISBN: 3902533013]
5. Prager R, Abrahamian H, Kautzky-Willer A, **Ludvik B**, Schütz-Fuhrmann I, Weitgasser R: Diabetesmanagement mit Insulinanaloga. UNI-MED Verlag AG, 1. Auflage, 2008 [ISBN 978-3-89599-919-2]